This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the potential of Lucid-MS to address limitations of existing multiple sclerosis (“MS”) treatments. The editorial highlights Quantum BioPharma’s U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, the trial would mark the first time a drug based on this mechanism is tested in people living with MS.
To view the full press release, visit https://nnw.fm/whtAF
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer